{
    "clinical_study": {
        "@rank": "78891", 
        "arm_group": [
            {
                "arm_group_label": "Regorafenib (severe impairment)", 
                "arm_group_type": "Experimental", 
                "description": "Cancer subjects with severe renal impairment"
            }, 
            {
                "arm_group_label": "Regorafenib (normal impairment)", 
                "arm_group_type": "Experimental", 
                "description": "Cancer subjects with normal or mildly impaired renal function"
            }
        ], 
        "brief_summary": {
            "textblock": "To characterize the pharmacokinetics and safety of regorafenib in cancer subjects with\n      severe renal impairment when compared to the Control group (cancer subjects with normal or\n      mildly impaired renal function)"
        }, 
        "brief_title": "Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with histologically confirmed, locally advanced or metastatic, refractory\n             solid tumors who are not candidates for standard therapy\n\n          -  Male or female subject \u2265 18 years of age\n\n          -  Women of childbearing potential must have a negative urine pregnancy test performed\n             within 7 days before start of study treatment\n\n          -  Life expectancy at least 8 weeks\n\n          -  Adequate bone marrow, and liver function as assessed by the following laboratory\n             requirements conducted within 7 days of starting the study treatment\n\n          -  For subjects with NORMAL OR MILDLY IMPAIRED RENAL FUNCTION (Control group); to be\n             tested within 7 days of starting the study treatment:\n\n               -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2\n\n               -  Estimated creatinine clearance (CLcr) \u2265 60 mL/min as calculated using the\n                  Cockcroft-Gault equation\n\n          -  For subjects with SEVERELY IMPAIRED renal function; to be tested within 7 days of\n             starting the study treatment:\n\n               -  CLcr 15-29 mL/min as calculated using the Cockcroft-Gault equation\n\n        Exclusion Criteria:\n\n          -  Symptomatic metastatic brain or meningeal tumors\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days\n             before start of study medication\n\n          -  History of organ allograft\n\n          -  Non-healing wound, skin ulcer, or bone fracture\n\n          -  Pheochromocytoma\n\n          -  Uncontrolled concurrent medical illness including uncontrolled hypertension\n\n          -  History of cardiac disease\n\n          -  Pleural effusion or ascites that causes respiratory compromise\n\n          -  Interstitial lung disease with ongoing signs and symptoms at the time of screening\n\n          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident\n             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism\n             within 6 months before the start of study medication\n\n          -  Subjects with evidence or history of bleeding diathesis; any hemorrhage or bleeding\n             event NCI-CTCAE Grade \u2265 3 or higher within 4 weeks of start of investigational\n             treatment\n\n          -  Dehydration NCI-CTCAEversion 4.0 Grade \u2265 1\n\n          -  Unresolved toxicity higher than NCI-CTCAE version 4.0 Grade 1 attributed to any prior\n             therapy/procedure (excluding alopecia or anemia or grade 2 neuropathy that is not\n             reversible due to oxaliplatin)\n\n          -  Seizure disorder requiring anticonvulsant therapy (such as steroids or\n             anti-epileptics)\n\n          -  For subjects with SEVERELY IMPAIRED renal function:\n\n               -  Renal failure requiring hemo- or peritoneal dialysis\n\n               -  Acute renal failure\n\n               -  Acute nephritis\n\n               -  Nephrotic syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853046", 
            "org_study_id": "16653"
        }, 
        "intervention": {
            "arm_group_label": [
                "Regorafenib (severe impairment)", 
                "Regorafenib (normal impairment)"
            ], 
            "description": "Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 (at least 6 days) followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days).", 
            "intervention_name": "Regorafenib (Stivarga, BAY73-4506)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Regorafenib", 
            "pharmacokinetics", 
            "safety", 
            "severe renal impairment", 
            "Solid tumors"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263-0001"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 1Z2"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2L 4M1"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_contact_backup": {
            "last_name": "For trial location information (Phone Menu Options '3' or '4')", 
            "phone": "(+)1-888-84 22937"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "AUC(0-tlast) [area under the concentration-time curve after single dose from time zero to the last data point >LLOQ (lower limit of quantification)] for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose"
            }, 
            {
                "description": "based on population PK model evaluation", 
                "measure": "AUC(0-24)md [Area under the concentration-time curve after multiple dose from time zero to 24 hours for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose"
            }, 
            {
                "measure": "AE,ur(0-24) (amount of drug excreted via urine during the collection interval 0-24 hours post administration) for metabolites M-7 and M-8", 
                "safety_issue": "No", 
                "time_frame": "Days 1-2: 0-10 and 10-24 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853046"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tumor response assessment for measurable lesions according to RECIST, v1.1 (Response Evaluation Criteria in Solid Tumors)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Assessment of bone metastases by scintigraphy (bone scan)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "AUC (area under the plasma concentration vs. time curve from zero to infinity after single (first) dose) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "AUC(0-24) (AUC from time zero to 24 hours p.a. after first-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "Cmax (maximum drug concentration in plasma after first dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "tmax (time to reach maximum drug concentration in plasma after single (first) dose) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "tlast (time of last data point >LLOQ) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "t1/2 (half-life associated with the terminal slope) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "CL/F (total body clearance of drug after extravascular administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "Vz/F (apparent volume of distribution during terminal phase after single oral administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "AUC(0-24)md ((AUC(0-24) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose"
            }, 
            {
                "description": "based on population PK model evaluation", 
                "measure": "AUC(0-24)md ((AUC(0-24) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "Cmax,md (Cmax after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "AUC(0-tlast)md (AUC(0-tlast) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose"
            }, 
            {
                "description": "based on population PK model evaluation and on actual individual dosing schedule", 
                "measure": "AUC(0-tlast)md (AUC(0-tlast) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose"
            }, 
            {
                "description": "based on population PK model evaluation and on the nominal dosing schedule", 
                "measure": "AUC(0-tlast)md (AUC(0-tlast) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "tmax,md (time to reach maximum drug concentration in plasma after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose"
            }, 
            {
                "description": "based on non-compartmental PK evaluation", 
                "measure": "tlast,md (tlast after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5", 
                "safety_issue": "No", 
                "time_frame": "Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}